Recursion Pharmaceuticals, Inc. (RXRX)
NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
At close: 04:00PM EDT
Pre-market:
Currency in USD
Valuation measures4
| Market cap (intra-day) | 2.23B |
| Enterprise value | 1.98B |
| Trailing P/E | N/A |
| Forward P/E | N/A |
| PEG ratio (5-yr expected) | N/A |
| Price/sales (ttm) | 45.40 |
| Price/book (mrq) | 5.56 |
| Enterprise value/revenue | 43.86 |
| Enterprise value/EBITDA | N/A |
Trading information
Stock price history
| Beta (5Y monthly) | 0.86 |
| 52-week change 3 | 23.71% |
| S&P500 52-week change 3 | 24.96% |
| 52-week high 3 | 16.75 |
| 52-week low 3 | 4.97 |
| 50-day moving average 3 | 8.72 |
| 200-day moving average 3 | 8.92 |
Share statistics
| Avg vol (3-month) 3 | 4.69M |
| Avg vol (10-day) 3 | 4.54M |
| Shares outstanding 5 | 230.27M |
| Implied shares outstanding 6 | 252.22M |
| Float 8 | 191.92M |
| % held by insiders 1 | 5.20% |
| % held by institutions 1 | 97.21% |
| Shares short (15 May 2024) 4 | 42.37M |
| Short ratio (15 May 2024) 4 | 8.27 |
| Short % of float (15 May 2024) 4 | 26.88% |
| Short % of shares outstanding (15 May 2024) 4 | 17.83% |
| Shares short (prior month 15 Apr 2024) 4 | 38.7M |
Dividends & splits
| Forward annual dividend rate 4 | N/A |
| Forward annual dividend yield 4 | N/A |
| Trailing annual dividend rate 3 | 0.00 |
| Trailing annual dividend yield 3 | 0.00% |
| 5-year average dividend yield 4 | N/A |
| Payout ratio 4 | 0.00% |
| Dividend date 3 | N/A |
| Ex-dividend date 4 | N/A |
| Last split factor 2 | N/A |
| Last split date 3 | N/A |
Financial highlights
Fiscal year
| Fiscal year ends | 31 Dec 2023 |
| Most-recent quarter (mrq) | 31 Mar 2024 |
Profitability
| Profit margin | 0.00% |
| Operating margin (ttm) | -697.64% |
Management effectiveness
| Return on assets (ttm) | -39.82% |
| Return on equity (ttm) | -85.19% |
Income statement
| Revenue (ttm) | 46.23M |
| Revenue per share (ttm) | 0.21 |
| Quarterly revenue growth (yoy) | 13.70% |
| Gross profit (ttm) | N/A |
| EBITDA | -349.54M |
| Net income avi to common (ttm) | -354.11M |
| Diluted EPS (ttm) | -1.63 |
| Quarterly earnings growth (yoy) | N/A |
Balance sheet
| Total cash (mrq) | 296.33M |
| Total cash per share (mrq) | 1.25 |
| Total debt (mrq) | 50.97M |
| Total debt/equity (mrq) | 12.71% |
| Current ratio (mrq) | 4.65 |
| Book value per share (mrq) | 1.69 |
Cash flow statement
| Operating cash flow (ttm) | -316.76M |
| Levered free cash flow (ttm) | -208.61M |
© 2024 Yahoo. All rights reserved.